XSTO
CLBIO
Market cap36mUSD
Oct 09, Last price
13.70SEK
1D
-0.36%
1Q
-21.49%
Jan 2017
35.64%
IPO
41.28%
Name
Corline Biomedical AB
Chart & performance
P/E
—
P/S
46.79
EPS
—
Div yield, %
—
Shrs. gr., 5y
7.60%
Rev. gr., 5y
15.66%
Revenues
8m
-21.73%
Net income
-15m
L-36.56%
CFO
-18m
L+104.76%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.
Headquarters & legal address
Lefflersgatan 5
Uppsala 754 50
SE
Uppsala 754 50
SE
Previous name
Corline Systems Aktiebolag
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||